An Open-Label, Non-Randomized, Multicenter, Phase II Study to Study the Efficacy of Talquetamab (JNJ-64407564) and Lenalidomide as Post Stem Cell Transplant Maintenance in Multiple Myeloma (OPTIMMAL)

Multiple myeloma (MM) is a heterogenous plasma cell malignancy characterized by clonal proliferation of plasma cells and organ damage. Autologous transplantation with high dose chemotherapy is the standard of care in frontline treatment of eligible patients with MM.

Start Date01 Nov 2025

Sponsor / Collaborator

Stanford University

[+1]

NCT06792825

/ Not yet recruitingPhase 2IIT

HM2023-43: A Phase 2 Trial of Tafasitamab in Combination With Lenalidomide+Rituximab in Treatment-naive Follicular Lymphoma and Marginal Zone Lymphoma

The study follows a Simon's two-stage phase II trial design to evaluate the safety and efficacy of tafasitamab added to rituximab and lenalidomide for two treatment-naïve, parallel, independent cohorts: follicular lymphoma (FL) and marginal zone lymphoma (MZ). Each cohort, FL and MZ, will be evaluated separately. This study is presented to the patient and consent is signed prior to the initiation of treatment for their primary malignancy.

Start Date01 Jul 2025

Sponsor / Collaborator

University of Minnesota Masonic Cancer Center

[+1]

NCT06348147

/ Not yet recruitingPhase 2IIT

An Attenuated Schedule Dara-RVd Induction for Patients With Newly Diagnosed Multiple Myeloma Who Are Eligible for Autologous Stem Cell Transplantation

This Phase II hybrid decentralized trial will examine the effect of daratumumab-based quadruplet induction therapy administered at an attenuated schedule in subjects with newly diagnosed multiple myeloma (NDMM) who are eligible for standard-of-care autologous stem cell transplantation (ASCT). Daratumumab, lenalidomide, bortezomib, and dexamethasone (Dara-RVd) have recently become a standard induction regimen for patients with NDMM who are eligible for ASCT in the United States. As implemented in clinical trials, Dara-RVd involves twice weekly bortezomib administration, which is inconvenient for patients and may result in increased rates of limiting toxicity, such as peripheral neuropathy. Adoption of alternate schedules involving once-weekly bortezomib is common in real-world practice, however a paucity of prospective data supporting this practice exists.
This study examines the efficacy of an attenuated Dara-RVd schedule involving once-weekly bortezomib dosing.

Start Date01 Mar 2025

Sponsor / Collaborator

UNC Lineberger Comprehensive Cancer Center

100 Clinical Results associated with Lenalidomide

100 Translational Medicine associated with Lenalidomide

100 Patents (Medical) associated with Lenalidomide

8,795

Literatures (Medical) associated with Lenalidomide

01 Mar 2025·American journal of ophthalmology case reports

Periorbital necrobiotic xanthogranuloma resolved with three years of systemic lenalidomide treatment

Article

Author: Foster, Jill A ; Hofer, Llwyatt K ; Buckley, Kaila A

Purpose:

To describe a case report of the successful management of necrobiotic xanthogranuloma (NXG), a rare periorbital disease.

Observations:

A 61-year-old patient presented with bilateral upper and lower lid lesions which were initially misdiagnosed as xanthelasmas and later confirmed to be NXG. Further investigation also uncovered a diagnosis of multiple myeloma. The patient was started on a lenalidomide treatment for his multiple myeloma, specifically chosen by a coalition of Hematology/Oncology, Dermatology, Internal Medicine and Oculoplastics, to simultaneously treat his NXG. His periocular lesions were monitored for response without additional intervention. It was initially difficult to determine if the patient's periocular involvement was improving due to conflicting concurrent ulceration and decreased height of the lesions. At 18 months, improvement became apparent. After three years of treatment, the patient's periocular lesions had clinically disappeared. Follow-up with the patient confirmed that there had been no return of either the NXG or multiple myeloma three years after treatment cessation.

Conclusions and Importance:

This case contributes to the existing literature by documenting complete resolution of NXG after three years of lenalidomide treatment, which is a much longer treatment duration than typically described in the literature. These observations alert treating physicians that a longer treatment interval may be needed to address NXG.

01 Mar 2025·EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

Design, synthesis and biological evaluation of bisnoralcohol derivatives as novel IRF4 inhibitors for the treatment of multiple myeloma

Article

Author: Zhang, De-Jie ; Ding, Xin ; Yi, Zhengfang ; Li, Chen-Chen ; Liu, Mingyao ; Wu, Yujie ; Wu, Min ; Zhang, Lin ; Qiu, Wen-Wei ; Zhang, Jing-Zan

Interferon regulatory factor 4 (IRF4) is specifically overexpressed in multiple myeloma (MM) and mediates MM progression and survival, making it an emerging target for MM treatment. However, no chemical entity with a defined structure capable of directly binding to and inhibiting IRF4 has been reported. We screened our small library of steroid analogs and identified bisnoralcohol (BA) derivative 18 as a novel hit compound capable of inhibiting IRF4, with an IC₅₀ of 13.46 μM. Based on 18, a series of BA derivatives was synthesized and evaluated for their inhibitory effects on IRF4 and antiproliferative activities against MM cell lines. Among these compounds, 41 (SH514) exhibited the highest potency, with an IC₅₀ value of 2.63 μM for inhibiting IRF4, and IC₅₀ values of 0.08 μM and 0.11 μM for inhibiting the proliferation of IRF4-high-expressing NCI-H929 and MM.1R MM cells, respectively. SH514 can bind to the IRF4-DBD domain with a KD of 1.28 μM. SH514 selectively and potently inhibits IRF4-high-expressing MM cells over IRF4-low-expressing MM cells. Mechanistic studies demonstrated that SH514 suppresses the downstream genes of IRF4, including CCNC, CANX, E2F5, CMYC, HK2, and Blimp1, and inhibited the expression of cell cycle-related proteins CDC2, Cyclin B1, Cyclin D1, Cyclin E1, and CMYC in MM cells. In vivo, SH514 effectively inhibited the proliferation of MM tumors, showing much better antitumor efficacy than the clinical drug lenalidomide, and exhibited no significant toxicity. Thus, these IRF4 inhibitors could serve as promising leads for the development of novel anti-multiple myeloma agents.

01 Feb 2025·ESMO Open

Outcomes and prognostic indicators in daratumumab-refractory multiple myeloma: a multicenter real-world study of elotuzumab, pomalidomide, and dexamethasone in 247 patients

Article

Author: Conticello, C ; Musso, M ; Amico, V ; Martino, E A ; Casaluci, G M ; Accardi, F ; Palmieri, S ; Bruzzese, A ; Franceschini, L ; Uccello, G ; Barbieri, E ; Offidani, M ; Cerchione, C ; Zambello, R ; Gozzetti, A ; Maroccia, A ; Palumbo, G ; De Magistris, C ; Tarantini, G ; Derudas, D ; Brunori, M ; Petrucci, M T ; Quaresima, M ; Barilà, G ; Pettine, L ; Vigna, E ; Galli, M ; Morabito, F ; Neri, A ; Mele, G ; Califano, C ; Sgherza, N ; Vincelli, I D ; Di Renzo, N ; Mina, R ; Zamagni, E ; Fontana, R ; Rizzi, R ; Mancuso, K ; Reddiconto, G ; Bertuglia, G ; Ria, R ; Curci, P ; Amendola, A ; Di Raimondo, F ; Nappi, D ; Musto, P ; Bongarzoni, V ; Rago, A ; Rossini, B ; Mangiacavalli, S ; Della Pepa, R ; Gentile, M ; Tripepi, G ; Cotzia, E

BACKGROUND:

Daratumumab-refractory multiple myeloma (Dara-R MM) presents a significant treatment challenge. This study aimed to evaluate the efficacy and survival outcomes of elotuzumab, pomalidomide, and dexamethasone (EloPd) in a large, real-world cohort of patients with Dara-R MM, with particular focus on progression-free survival (PFS) and overall survival (OS).

MATERIALS AND METHODS:

This retrospective analysis included 247 Dara-R MM patients treated with EloPd. All patients were also refractory to lenalidomide, with 51.4% to a proteasome inhibitor, thus classified as triple-class refractory (TCR). Survival risk-scoring systems for PFS (progression-free risk score-PRS_DaraR) and OS (survival risk score-SRS_DaraR) were developed to stratify patients based on their risk profiles.

RESULTS:

The overall response rate was 52.6%, with a median PFS and OS of 6.6 and 17.0 months, respectively. The International Staging System (ISS) stages II and III, low hemoglobin (Hb) levels, the last therapy being daratumumab, and symptomatic relapse were identified as significant independent predictors of shorter PFS in multivariable analysis. In addition to advanced ISS stages, low Hb levels (<10.6 g/dl), symptomatic relapse, and refractory disease exhibited an independent negative impact on OS. Importantly, no significant differences in both PFS and OS were observed between TCR and non-TCR patients. Based on these multivariable analyses, we developed PRS_DaraR and SRS_DaraR according to the magnitude of the hazard ratio. In PRS_DaraR, 10.1% were low-risk, 41.3% intermediate, 43.3% high, and 5.3% very high-risk. The 12-month PFS probabilities were 86.3% (low), 67.6% (intermediate), 52.9% (high), and 31.8% (very high). For SRS_DaraR, 6.1% were low-risk, 47.8% intermediate, 19.4% high, and 26.7% very high. The 12-month OS probabilities were 90.9% (low), 75.7% (intermediate), 55.9% (high), and 32.6% (very high).

CONCLUSIONS:

This study supports EloPd as an effective treatment option in Dara-R MM patients, providing valuable disease control and acting as a potential bridge to newer therapies, such as CAR-T and bispecific antibodies.

645

News (Medical) associated with Lenalidomide

24 Jan 2025

·www.drugs.com

Lower Dexamethasone Dose Does Not Impair Survival in Multiple Myeloma

FRIDAY, Jan. 24, 2025 -- For patients with newly diagnosed multiple myeloma (NDMM) receiving dexamethasone induction, dose reductions do not negatively impact survival, according to a study published online Jan. 2 in Blood . Rahul Banerjee, M.D., from the Fred Hutchinson Cancer Center in Seattle, and colleagues conducted a secondary pooled analysis of the SWOG 0777 and SWOG 1211 studies, which examined lenalidomide and dexamethasone alone, with or without bortezomib and with or without elotuzumab for NDMM. In all arms, the planned dexamethasone intensity was 40 to 60 mg weekly. Patients were classified as full-dose dexamethasone throughout induction (FD-DEX) or lowered-dose dexamethasone or discontinuation (LD-DEX), permitted for grade 3+ toxicities per both study protocols. The LD-DEX group included 373 patients (69 percent) of the 541 evaluated. The researchers found that progression-free survival (PFS) and overall survival (OS) did not differ between the FD-DEX and LD-DEX groups. In the multivariate models, predictors of PFS and OS were treatment arm, age 70 years or older, and thrombocytopenia. "Dexamethasone dose reductions <40 to 60 mg per week are quite common even in the setting of clinical trials," the authors write. "These dose reductions do not appear to negatively impact PFS or OS. We encourage future trials to investigate lowered-dose dexamethasone strategies prospectively, either at treatment onset or within a few cycles of treatment initiation." Several authors disclosed ties to the biopharmaceutical industry.

Clinical Result

22 Jan 2025

·pipelinereview.com

Sarclisa approved in the EU as the first anti-CD38 therapy in combination with standard-of-care VRd to treat transplant-ineligible newly diagnosed multiple myeloma

PARIS, France I January 22, 2025 I Following the adoption of a positive opinion by the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP), the EU has approved Sarclisa in combination with a standard-of-care regimen, bortezomib, lenalidomide, and dexamethasone (VRd), for the treatment of adult patients with newly diagnosed multiple myeloma (NDMM) ineligible for autologous stem cell transplant (ASCT), based on data from the IMROZ phase 3 study . With the expanded marketing authorization, Sarclisa is the first anti-CD38 therapy in combination with VRd in this patient population in the EU. Olivier Nataf Global Head of Oncology at Sanofi “While there have been many important advancements in multiple myeloma treatment over the past decade, there remains a significant unmet need in the front-line setting, particularly for transplant-ineligible patients. With today’s decision the 27 countries in the EU will have access to a potentially transformative new combination regimen, marking a significant step forward in our mission to make a meaningful difference in multiple myeloma treatment.” In September 2024, the US Food and Drug Administration (FDA) approved Sarclisa in combination with VRd for the treatment of adult patients with NDMM who are not eligible for ASCT, representing the first global approval for Sarclisa in the front-line setting. In addition, the FDA granted orphan drug exclusivity for Sarclisa in the approved indication. Beyond the US and the EU, regulatory submissions for Sarclisa in NDMM not eligible for ASCT are under review in Japan and in China. About Sarclisa Sarclisa (isatuximab) is a CD38 monoclonal antibody that binds to a specific epitope on the CD38 receptor on MM cells, inducing distinct antitumor activity. It is designed to work through multiple mechanisms of action including programmed tumor cell death (apoptosis) and immunomodulatory activity. CD38 is highly and uniformly expressed on the surface of MM cells, making it a target for antibody-based therapeutics such as Sarclisa. In the US, the non-proprietary name for Sarclisa is isatuximab-irfc, with irfc as the suffix designated in accordance with nonproprietary naming of biological products guidance for industry issued by the US FDA. Currently, Sarclisa is approved in more than 50 countries, including the US and in the EU, across three indications. Based on the ICARIA-MM phase 3 study, Sarclisa is approved in combination with pomalidomide and dexamethasone (Pd) for the treatment of patients with relapsed or refractory MM (R/R MM) who have received ≥2 prior therapies, including lenalidomide and a proteasome inhibitor, and who progressed on last therapy. Based on the IKEMA phase 3 study, Sarclisa is also approved in 50 countries in combination with carfilzomib and dexamethasone, including in the US for the treatment of patients with R/R MM who have received 1–3 prior lines of therapy and in the EU for patients with MM who have received at least 1 prior therapy. In the US and EU, Sarclisa is approved in combination with VRd as a front-line treatment option for adult patients with NDMM, who are not eligible for ASCT, based on the IMROZ phase 3 study. Sanofi continues to advance Sarclisa as part of a patient-centric clinical development program, which includes several phase 2 and phase 3 studies across the MM treatment continuum spanning six potential indications. In addition, the company is evaluating a subcutaneous administration method for Sarclisa in clinical studies. The safety and efficacy of Sarclisa has not been evaluated by any regulatory authority outside of its approved indications and methods of delivery. In striving to become the number one immunoscience company globally, Sanofi remains committed to advancing oncology innovation. Through focused strategic decisions the company has reshaped and prioritized its pipeline, leveraging its expertise in immunoscience to drive progress. Efforts are centered on difficult-to-treat often rare cancers such as select hematologic malignancies and solid tumors with critical unmet needs, including multiple myeloma, acute myeloid leukemia, certain types of lymphomas, as well as gastrointestinal and lung cancers. For more information on Sarclisa clinical studies, please visit www.clinicaltrials.gov . About Sanofi We are an innovative global healthcare company, driven by one purpose: we chase the miracles of science to improve people’s lives. Our team, across the world, is dedicated to transforming the practice of medicine by working to turn the impossible into the possible. We provide potentially life-changing treatment options and life-saving vaccine protection to millions of people globally, while putting sustainability and social responsibility at the center of our ambitions. Sanofi is listed on EURONEXT: SAN and NASDAQ: SNY SOURCE: Sanofi

Drug ApprovalPhase 3Orphan DrugImmunotherapy

22 Jan 2025

·www.globenewswire.com

Press Release: Sarclisa approved in the EU as the first anti-CD38 therapy in combination with standard-of-care VRd to treat transplant-ineligible newly diagnosed multiple myeloma

Sarclisa approved in the EU as the first anti-CD38 therapy in combination with standard-of-care VRd to treat transplant-ineligible newly diagnosed multiple myeloma Approval is based on positive results from the IMROZ phase 3 study, demonstrating Sarclisa in combination with standard-of-care treatment significantly improved PFS, compared to the standard of care alone in TI NDMMRepresents third indication in the EU, including two for the treatment of adult patients with R/R MM, and one in NDMM Paris, January 22, 2025. Following the adoption of a positive opinion by the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP), the EU has approved Sarclisa in combination with a standard-of-care regimen, bortezomib, lenalidomide, and dexamethasone (VRd), for the treatment of adult patients with newly diagnosed multiple myeloma (NDMM) ineligible for autologous stem cell transplant (ASCT), based on data from the IMROZ phase 3 study. With the expanded marketing authorization, Sarclisa is the first anti-CD38 therapy in combination with VRd in this patient population in the EU. Olivier NatafGlobal Head of Oncology at Sanofi“While there have been many important advancements in multiple myeloma treatment over the past decade, there remains a significant unmet need in the front-line setting, particularly for transplant-ineligible patients. With today’s decision the 27 countries in the EU will have access to a potentially transformative new combination regimen, marking a significant step forward in our mission to make a meaningful difference in multiple myeloma treatment.” In September 2024, the US Food and Drug Administration (FDA) approved Sarclisa in combination with VRd for the treatment of adult patients with NDMM who are not eligible for ASCT, representing the first global approval for Sarclisa in the front-line setting. In addition, the FDA granted orphan drug exclusivity for Sarclisa in the approved indication. Beyond the US and the EU, regulatory submissions for Sarclisa in NDMM not eligible for ASCT are under review in Japan and in China. About SarclisaSarclisa (isatuximab) is a CD38 monoclonal antibody that binds to a specific epitope on the CD38 receptor on MM cells, inducing distinct antitumor activity. It is designed to work through multiple mechanisms of action including programmed tumor cell death (apoptosis) and immunomodulatory activity. CD38 is highly and uniformly expressed on the surface of MM cells, making it a target for antibody-based therapeutics such as Sarclisa. In the US, the non-proprietary name for Sarclisa is isatuximab-irfc, with irfc as the suffix designated in accordance with nonproprietary naming of biological products guidance for industry issued by the US FDA. Currently, Sarclisa is approved in more than 50 countries, including the US and in the EU, across three indications. Based on the ICARIA-MM phase 3 study, Sarclisa is approved in combination with pomalidomide and dexamethasone (Pd) for the treatment of patients with relapsed or refractory MM (R/R MM) who have received ≥2 prior therapies, including lenalidomide and a proteasome inhibitor, and who progressed on last therapy. Based on the IKEMA phase 3 study, Sarclisa is also approved in 50 countries in combination with carfilzomib and dexamethasone, including in the US for the treatment of patients with R/R MM who have received 1–3 prior lines of therapy and in the EU for patients with MM who have received at least 1 prior therapy. In the US and EU, Sarclisa is approved in combination with VRd as a front-line treatment option for adult patients with NDMM, who are not eligible for ASCT, based on the IMROZ phase 3 study. Sanofi continues to advance Sarclisa as part of a patient-centric clinical development program, which includes several phase 2 and phase 3 studies across the MM treatment continuum spanning six potential indications. In addition, the company is evaluating a subcutaneous administration method for Sarclisa in clinical studies. The safety and efficacy of Sarclisa has not been evaluated by any regulatory authority outside of its approved indications and methods of delivery. In striving to become the number one immunoscience company globally, Sanofi remains committed to advancing oncology innovation. Through focused strategic decisions the company has reshaped and prioritized its pipeline, leveraging its expertise in immunoscience to drive progress. Efforts are centered on difficult-to-treat often rare cancers such as select hematologic malignancies and solid tumors with critical unmet needs, including multiple myeloma, acute myeloid leukemia, certain types of lymphomas, as well as gastrointestinal and lung cancers. For more information on Sarclisa clinical studies, please visit www.clinicaltrials.gov. About Sanofi We are an innovative global healthcare company, driven by one purpose: we chase the miracles of science to improve people’s lives. Our team, across the world, is dedicated to transforming the practice of medicine by working to turn the impossible into the possible. We provide potentially life-changing treatment options and life-saving vaccine protection to millions of people globally, while putting sustainability and social responsibility at the center of our ambitions.Sanofi is listed on EURONEXT: SAN and NASDAQ: SNY Media RelationsSandrine Guendoul | + 33 6 25 09 14 25 | sandrine.guendoul@sanofi.com Evan Berland | +1 215 432 0234 | evan.berland@sanofi.com Nicolas Obrist | + 33 6 77 21 27 55 | nicolas.obrist@sanofi.com Léo Le Bourhis | + 33 6 75 06 43 81 | leo.lebourhis@sanofi.com Victor Rouault | + 33 6 70 93 71 40 | victor.rouault@sanofi.comTimothy Gilbert | + 1 516 521 2929 | timothy.gilbert@sanofi.com Investor RelationsThomas Kudsk Larsen |+ 44 7545 513 693 | thomas.larsen@sanofi.com Alizé Kaisserian | + 33 6 47 04 12 11 | alize.kaisserian@sanofi.comFelix Lauscher | + 1 908 612 7239 | felix.lauscher@sanofi.com Keita Browne | + 1 781 249 1766 | keita.browne@sanofi.comNathalie Pham | + 33 7 85 93 30 17 | nathalie.pham@sanofi.comTarik Elgoutni | + 1 617 710 3587 | tarik.elgoutni@sanofi.com Thibaud Châtelet | + 33 6 80 80 89 90 | thibaud.chatelet@sanofi.com Sanofi forward-looking statementsThis press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates regarding the marketing and other potential of the product, or regarding potential future revenues from the product. Forward-looking statements are generally identified by the words “expects”, “anticipates”, “believes”, “intends”, “estimates”, “plans” and similar expressions. Although Sanofi’s management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Sanofi, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, unexpected regulatory actions or delays, or government regulation generally, that could affect the availability or commercial potential of the product, the fact that product may not be commercially successful, the uncertainties inherent in research and development, including future clinical data and analysis of existing clinical data relating to the product, including post marketing, unexpected safety, quality or manufacturing issues, competition in general, risks associated with intellectual property and any related future litigation and the ultimate outcome of such litigation, and volatile economic and market conditions, and the impact that pandemics or other global crises may have on us, our customers, suppliers, vendors, and other business partners, and the financial condition of any one of them, as well as on our employees and on the global economy as a whole. The risks and uncertainties also include the uncertainties discussed or identified in the public filings with the SEC and the AMF made by Sanofi, including those listed under “Risk Factors” and “Cautionary Statement Regarding Forward-Looking Statements” in Sanofi’s annual report on Form 20-F for the year ended December 31, 2023. Other than as required by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking information or statements. All trademarks mentioned in this press release are the property of the Sanofi group. Attachment Press Release

Phase 3Drug ApprovalClinical ResultImmunotherapyOrphan Drug

100 Deals associated with Lenalidomide

External Link

KEGG	Wiki	ATC	Drug Bank
D04687	Lenalidomide	L04AX04	DB00480

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Marginal Zone B-Cell Lymphoma	US	Bristol Myers Squibb Co.	28 May 2019
Adult T-Cell Leukemia-Lymphoma	JP	Bristol-Myers Squibb KK	02 Mar 2017
Chromosome 5q Deletion Syndrome	EU	Bristol-Myers Squibb Pharma EEIG	14 Jun 2007
Chromosome 5q Deletion Syndrome	IS	Bristol-Myers Squibb Pharma EEIG	14 Jun 2007
Chromosome 5q Deletion Syndrome	LI	Bristol-Myers Squibb Pharma EEIG	14 Jun 2007
Chromosome 5q Deletion Syndrome	NO	Bristol-Myers Squibb Pharma EEIG	14 Jun 2007
Follicular Lymphoma	EU	Bristol-Myers Squibb Pharma EEIG	14 Jun 2007
Follicular Lymphoma	IS	Bristol-Myers Squibb Pharma EEIG	14 Jun 2007
Follicular Lymphoma	LI	Bristol-Myers Squibb Pharma EEIG	14 Jun 2007
Follicular Lymphoma	NO	Bristol-Myers Squibb Pharma EEIG	14 Jun 2007
Mantle-Cell Lymphoma	EU	Bristol-Myers Squibb Pharma EEIG	14 Jun 2007
Mantle-Cell Lymphoma	IS	Bristol-Myers Squibb Pharma EEIG	14 Jun 2007
Mantle-Cell Lymphoma	LI	Bristol-Myers Squibb Pharma EEIG	14 Jun 2007
Mantle-Cell Lymphoma	NO	Bristol-Myers Squibb Pharma EEIG	14 Jun 2007
Transfusion dependent anaemia	EU	Bristol-Myers Squibb Pharma EEIG	14 Jun 2007
Transfusion dependent anaemia	IS	Bristol-Myers Squibb Pharma EEIG	14 Jun 2007
Transfusion dependent anaemia	LI	Bristol-Myers Squibb Pharma EEIG	14 Jun 2007
Transfusion dependent anaemia	NO	Bristol-Myers Squibb Pharma EEIG	14 Jun 2007
Multiple Myeloma	US	Bristol Myers Squibb Co.	29 Jun 2006
Myelodysplastic Syndromes	US	Bristol Myers Squibb Co.	27 Dec 2005

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Plasmacytoma	Phase 3	US	Millennium Pharmaceuticals, Inc.	01 Dec 2015
Refractory Diffuse Large B-Cell Lymphoma Activated B-Cell Type	Phase 3	US	Celgene Corp.	17 Feb 2015
Refractory Diffuse Large B-Cell Lymphoma Activated B-Cell Type	Phase 3	CN	Celgene Corp.	17 Feb 2015
Refractory Diffuse Large B-Cell Lymphoma Activated B-Cell Type	Phase 3	JP	Celgene Corp.	17 Feb 2015
Refractory Diffuse Large B-Cell Lymphoma Activated B-Cell Type	Phase 3	AU	Celgene Corp.	17 Feb 2015
Refractory Diffuse Large B-Cell Lymphoma Activated B-Cell Type	Phase 3	BE	Celgene Corp.	17 Feb 2015
Refractory Diffuse Large B-Cell Lymphoma Activated B-Cell Type	Phase 3	CA	Celgene Corp.	17 Feb 2015
Refractory Diffuse Large B-Cell Lymphoma Activated B-Cell Type	Phase 3	CZ	Celgene Corp.	17 Feb 2015
Refractory Diffuse Large B-Cell Lymphoma Activated B-Cell Type	Phase 3	FR	Celgene Corp.	17 Feb 2015
Refractory Diffuse Large B-Cell Lymphoma Activated B-Cell Type	Phase 3	IE	Celgene Corp.	17 Feb 2015

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT05564052 (VEGA, CTgov)	Phase 2	Mantle-Cell Lymphoma	36	Ibrutinib+Rituximab (Arm A1: Ibrutinib 560 mg + Rituximab 375 mg/m^2)	pbrdgyhots(txcohbkwnk) = jkqyfynwrq uwddizfesh (alwqxedorh, dzwhxucoji - bocaupwqip) View more	-	13 Jan 2025
				Ibrutinib+Rituximab (Arm A2: Ibrutinib 420 mg + Rituximab 375 mg/m^2)	pbrdgyhots(txcohbkwnk) = iwldbhtmtz uwddizfesh (alwqxedorh, osiktohsoa - geravbkrgx) View more
NCT04680052 (inMIND, ASH2024) Manual	Phase 3	Follicular Lymphoma	548	Tafasitamab + Lenalidomide + Rituximab	jpvspllaug(xncfoclrgd) = arcyvblwlc fajercvhbf (elteytmsqv ) View more	Positive	10 Dec 2024
				Placebo + Lenalidomide + Rituximab	jpvspllaug(xncfoclrgd) = vecfejfzyy fajercvhbf (elteytmsqv ) View more
ASH2024 Manual	Phase 1/2	Mantle-Cell Lymphoma	36	Venetoclax 2IbrutinibPrednisoneObinutuzumabLenalidomide	grunjonwzq(rosxvklswc) = thrombocytopenia (14%), neutropenia (13%), and anemia (10%) gcwsbaffvh (hpjorzmxfm ) View more	Positive	09 Dec 2024
				Venetoclax 4IbrutinibPrednisoneObinutuzumabLenalidomide
ASH2024 Manual	Not Applicable	Multiple Myeloma First line	193	Ixazomib,LenalidomideeDexamethasonehasone (IRd)	nbsawdyuwp(rewzwwbiex) = oxdcoefand rdpqvsthyp (duksoevtlc, 11.2) View more	Positive	09 Dec 2024
				Bortezomib,LenalidomideeDexamethasonehasone (VRd)	nbsawdyuwp(rewzwwbiex) = swbajqxuol rdpqvsthyp (duksoevtlc, 3.9) View more
NCT03319667 (IMROZ, ASH2024) Manual	Phase 3	Multiple Myeloma First line	446	Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone (Isa-VRd)	xjxfdrtuhs(imrzzlsxzw) = qmrlirnotn wuhkixydet (luyxakgkxa ) View more	Positive	09 Dec 2024
				Bortezomib, Lenalidomide, and Dexamethasone (VRd)	xjxfdrtuhs(imrzzlsxzw) = ejuzjcegop wuhkixydet (luyxakgkxa ) View more
ASH2024 Manual	Phase 1	Diffuse Large B-Cell Lymphoma	22	Polatuzumab Vedotin+Zanubrutinib+Rituximab+Lenalidomide	lsyglgitcm(vfwbovryys) = hqntpabors rodgarayih (uvtwrnvbqf ) View more	Positive	09 Dec 2024
NCT03617731 (GMMG-HD7, ASH2024)	Phase 3	Multiple Myeloma CD38	662	Isatuximab, Lenalidomide, Bortezomib, Dexamethasone	lkgoogyvou(swochbvrfs) = eoixjhgjiz buzphpwgys (wignxzyzbg, 95% CI 0.52 - 0.94) View more	Positive	09 Dec 2024
				Lenalidomide, Bortezomib, Dexamethasone	lkgoogyvou(swochbvrfs) = fhgjoqncpt buzphpwgys (wignxzyzbg, 95% CI 46 - 48) View more
ASH2024	Not Applicable	Recurrent Multiple Myeloma	-	Belantamab mafodotin 1.4 mg/kg	ozxivdxagq(dywtaqubbq) = 89.5% experienced blurred vision vevsxuscsq (iamehxjuwa ) View more	-	09 Dec 2024
				Belantamab mafodotin 1.9 mg/kg
ASH2024	Not Applicable	Multiple Myeloma	-	Lenalidomide	vejsvimiwn(rkxcuyddnk) = deckwtfnsk curqdlhcku (pcghjilbvp, 1 - 12)	-	09 Dec 2024
NCT03011814 (ASH2024) Manual	Phase 2	Cutaneous T-Cell Lymphoma	25	Durvalumab	fviofxrwpv(zeynkeyact) = eeqtggnpgn odjohcptoz (pzlkshgajs ) View more	Positive	08 Dec 2024
				Durvalumab + Lenalidomide	fviofxrwpv(zeynkeyact) = vyropgjfox odjohcptoz (pzlkshgajs ) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis